机构：[1]The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China[2]Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China中山大学附属第二医院[3]Cancer Hospital Affiliated to the University of Chinese Academy of Sciences, Hangzhou, China浙江省肿瘤医院[4]Affiliated Hospital of Qingdao University, Qingdao, China[5]Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China[6]Cancer Hospital Affiliated to Fudan University, Shanghai, China[7]Jiangsu Provincial People’s Hospital, Nanjing, China[8]Cancer Hospital Affiliated to Harbin Medical University, Harbin, China[9]Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China[10]the First Affiliated Hospital of Nanchang University, Nanchang, China[11]Tsinghua University School of Medicine, Beijing, China[12]the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China浙江大学医学院附属第一医院[13]the Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[14]the Second Affiliated Hospital of Harbin Medical University, Harbin, China[15]Tianjin Cancer Hospital, Tianjin, China[16]Tumor Hospital of Peking University, Beijing, China[17]the First Affiliated Hospital of China Medical University, Shenyang, China[18]Guangdong Provincial People’s Hospital, Guangzhou, China[19]Air Force Medical University Affiliated Xijing Hospital, Xi’an, China[20]Fujian Provincial Tumor Hospital, Fuzhou, China[21]Tangshan People’s Hospital, Tangshan, China[22]Yunnan Provincial Cancer Hospital, Kunming, China[23]Anhui Provincial Hospital, Hefei, China[24]Affiliated Union Hospital of Fujian Medical University, Fuzhou, China[25]Liaoning Provincial Cancer Hospital, Shenyang, China[26]People Hospital, Peking University, Beijing, China[27]Cancer Hospital Affiliated to Fudan University, Shanghai, China[28]Sun Yat-sen University Cancer Center, Guangzhou, China[29]Shandong Provincial Cancer Hospital, Jinan, China[30]the First Hospital of Peking University, Beijing, China[31]Henan Provincial Cancer Hospital, Shijiazhuang, China河南省肿瘤医院[32]the First Medical Center of the Chinese PLA General Hospital, Beijing, China[33]Peking Union Medical College Hospital, Beijing, China[34]Beijing Institute of Biotechnology, Beijing, China
Developing guidelines for the diagnosis and treatment of common cancers in China based on the evidence-based practice, the availability of diagnosis and treatment products, and the up-to-date advances in precision medicine is one of the basic tasks of the Chinese Society of Clinical Oncology (CSCO). In recent years, the availability of medical resources has become a major concern in clinical guidelines, which is particularly important for developing countries or socioeconomically diverse countries and territories. China is the world's largest developing country, with a large territory and uneven economic and academic developments. The CSCO guidelines must take into account the differences in regional development, the availability of medicines and diagnostic methods, and the social value of cancer treatment. Therefore, for each clinical problem and intervention in the CSCO guidelines, the levels of evidence should be graded according to the currently available evidences and expert consensuses, and the grades of recommendations should be based on the availability and cost-effectiveness of the products. Protocols with high evidence level and good availability are used as the Level I recommendations; protocols with relatively high evidence level but slightly lower expert consensus or with poor availability are used as the Level II recommendations; and protocols that are clinically applicable but with low evidence level are regarded as the Level III recommendations. Based on the findings of clinical research at home and abroad and the opinions of CSCO experts, the CSCO guidelines determine the levels of recommendations for clinical application. The CSCO Guidance Working Group firmly believes that evidence-based, availability-concerned, and consensus-based guidelines will be more feasible for clinical practice in China. Again, any comments from our readers are greatly appreciated and will be considered in updates of these guidelines, so as to maintain the accuracy, fairness, and timeliness of the CSCO guidelines.
第一作者机构：[1]The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
通讯作者：
推荐引用方式(GB/T 7714)：
Zefei Jiang,Erwei Song,Xiaojia Wang,et al.Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)[J].TRANSLATIONAL BREAST CANCER RESEARCH.2020,1:doi:10.21037/tbcr-2020-2.
APA：
Zefei Jiang,Erwei Song,Xiaojia Wang,Haibo Wang,Xiang Wang...&Fengrui Xu.(2020).Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version).TRANSLATIONAL BREAST CANCER RESEARCH,1,
MLA：
Zefei Jiang,et al."Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)".TRANSLATIONAL BREAST CANCER RESEARCH 1.(2020)
